

Strengthening The Organizing and Reporting of Microbiome Studies (STORMS)

Chloe Mirzayi, Audrey Renson, Fatima Zohra, Shaimaa Elsafoury, Lora Kasselmann, Janneke van de Wijgert, Nicola Segata, Francesco Beghini, Kelly Eckenrode, Jenn Dowd*, Heidi E. Jones*, Levi Waldron*+

*Equal contribution

+corresponding author

Abstract

Background: Human microbiome research is interdisciplinary, making concise organizing and reporting of results across the different styles of epidemiology, biology, bioinformatics, and statistics a challenge. Commonly used reporting guidelines for observational or genetic studies lack key aspects specific to microbiome studies.

Methods: A multidisciplinary group of microbiome researchers reviewed elements of available reporting guidelines for observational and genetic studies, and adapted these for application to human microbiome studies. New reporting elements were developed for laboratory, bioinformatic, and statistical analysis specific to microbiome studies, and other parts of these checklists were streamlined to keep reporting manageable.

Results: STORMS is a 18-item checklist for reporting on human microbiome studies, organized into six sections covering all sections of a scientific publication, presented as a table with space for author-provided details and intended for inclusion in supplementary materials.

Conclusions: STORMS provides guidance for authors and standardization for interdisciplinary microbiome studies, facilitating complete and concise reporting.

Availability: STORMS is downloadable as a versioned spreadsheet from storms.waldronlab.io.

Introduction

Reporting the results of human microbiome research is challenging because it often involves approaches from microbiology, genomics, biomedicine, bioinformatics, statistics, and epidemiology. Combined with the novelty of the field, this has resulted in the development and application of a variety of methodological approaches, with inconsistent reporting of methods and results. While some efforts have been made to address reporting standards in microbiome

studies, (1) no comprehensive standardized guidelines spanning laboratory and epidemiological reporting have been proposed.

Reporting guidelines promote consistency in reporting and, as a consequence, encourage reproducibility and improved study design. Editorial adoption of the CONSolidated Standards Of Reporting Trials (CONSORT) guidelines, for example, has been associated with an increase in trial quality scores.(1,2) Other epidemiological reporting guidelines have seen broad adoption, such as Strengthening the Reporting of OBservational studies in Epidemiology (STROBE) and STrengthening the REporting of Genetic Association Studies (STREGA). The Enhancing the Quality and Transparency of health Research (EQUATOR) website lists over 400 research reporting guidelines, but none as of the time of writing address studies of the human microbiome and health.(3)

Epidemiological studies of the human microbiome face special considerations compared to other epidemiological studies and thus require specific reporting standards. In addition to standard elements of epidemiological study design, microbiome studies involve collection and handling of biological specimens, evolving approaches to laboratory processing with the potential for batch effects, bioinformatic processing, statistical analysis of high-dimensional data, and reporting of results on potentially thousands of microbial measures.(4–6) The field has not reached consensus on many of these aspects, so inconsistencies in reporting inhibit reproducibility and hamper efforts to draw conclusions across similar studies.

For these reasons, we convened a multi-disciplinary working group to develop guidelines for microbiome study reporting. Members of this group include epidemiologists, biostatisticians, bioinformaticians, and microbiologists. The checklist is designed to balance completeness with burden of use, and is applicable to a broad range of human microbiome study designs and analysis. The “Strengthening The Organizing and Reporting of Microbiome Studies (STORMS)” checklist can serve as a tool to organize study planning and manuscript preparation, to improve the clarity of manuscripts, and for reviewers and readers to assess these studies.

Methods

Origin and development

The origins of this project are rooted in a systematic review of papers examining the role of various microbiome sites and disease. The goal of this project is to curate and release a publicly available, standardized database of microbiome study findings to aid future research. This review has revealed a large amount of heterogeneity in reporting, particularly around concepts of epidemiology such as study design, confounding, and sources of bias, but also microbiome-specific issues around statistical approaches to test for and measure relative abundance, and the extent to which potential bias from batch exists are addressed. This heterogeneity highlighted the need for standardized reporting guidelines, similar to those used

in other fields of study. The curators determined that standardized reporting guidelines would streamline the review process, but would more importantly help researchers throughout the field of microbiome research communicate their findings effectively.

A multidisciplinary group of bioinformaticians, epidemiologists, biostatisticians, and microbiologists was convened to discuss microbiome reporting standards. The group began by reviewing existing study reporting standards including STROBE,(7) STREGA,(8) MICRO,(4) and STROGAR.(5) The group also reviewed existing articles containing recommendations for microbiome reporting.(9,10) The STROBE and STREGA guidelines were used as a starting point for the STORMS checklist, although inspiration was drawn from the other reporting standards reviewed as well.

Working along the reporting standards development guidelines recommended by EQUATOR, a comprehensive list of potential guideline items was created. From this list, group members added, modified, and removed items based on their expertise. After the first round of edits, the checklist was then applied to a recent microbiome study by group members. Comments, removals, and additions were harmonized after each round. Based on this process, additional changes, simplifications, and clarifications were made with the goal of creating a streamlined and user-friendly checklist. This process was repeated until there was a group consensus that the checklist was ready for use. Outside subject matter experts were invited to review the guidelines and provide feedback and additional revisions were made based on their comments.

Results

Checklist

The latest version of the checklist at time of publication is presented in Table 1. Of the items in the latest version in the STORMS checklist, nine items or subitems were unchanged from STROBE, five were modified from STROBE, one was modified from STREGA, and 27 new guidelines were developed. Rationale for new and modified items are presented below. Documentation of items unmodified from STROBE and STREGA were presented in the publications of those checklists.

Abstract

Along with commonly included abstract materials such as a basic description of the participants and results, authors should report the study design(11)--such as case-control, cohort, or randomized control trial--in the abstract of their article (Item 1.0), as required by other reporting guidelines. Communicating study design in the abstract allows readers to quickly categorize the type of evidence provided.

Introduction

The introduction should clearly describe the underlying background, evidence, or theory that motivated the current study (Item 2.0). Among other possibilities, this could include pilot study data, previous findings from a similar study or topic, or a biologically plausible mechanism that has been proposed. This clarifies for the reader the motivations for the present study. If the study is exploratory in nature, explain what motivated the current exploration and the goals of the exploratory study.

Methods

Participants

The methods section should contain sufficient information for study replicability. When describing the participants in the study, the population of interest should be described and then how participants were sampled from the target population should be reported (Item 3.0). Because participant characteristics such as environment,(12) demographics,(13) and geography(14) can have important effects on the microbiome, it is essential to include this description. Specific criteria used to assess potential participants for eligibility in the study should also be reported, including both inclusion and exclusion criteria (Item 3.1). This is expanded from STROBE which requires eligibility criteria, but does not specify that both inclusion and exclusion criteria should be reported in detail.

The final analytic sample size should be stated and the reason for any exclusion of participants at any step of the recruitment or laboratory processes (Item 3.2). STROBE suggests using a flow diagram to show when and why participants were removed from the study. If participants were lost to follow-up or did not complete all assessments in a longitudinal study, time-point specific sample sizes should also be reported (Item 3.3). Additionally, studies that matched exposed to unexposed participants should describe what variables were used in matching (Item 3.4).

Laboratory

Describe laboratory methods in sufficient detail to allow replication. The handling of lab samples should be described, including sampling procedure (Item 4.0), storage, handling, processing, and contaminant analysis or negative controls (Item 4.3). Batch effects should be discussed as a potential source of confounding, including steps taken to ensure batch effects do not overlap with exposures or outcomes of interest (Item 4.1).(15) Library preparation, sequencing platform, and references to protocols with versions, should be stated (Item 4.4).

Data sources/measurement

For non-microbiome data (e.g. health outcomes, participant socioeconomic characteristics, environmental variables), the measurement of each variable should be described (Item 5.0). For instance, participant gender and age could be obtained from electronic medical records or from

a questionnaire distributed to participants; this data source should be described. Limitations of measurement may also be discussed including potential bias due to misclassification or missing data as well as any attempts made to address these measurement issues.

Research design considerations for causal inference

Observational data is often used to test associations that aim to infer cause and effect. Methods include, for example, the use of multivariable analysis or matching to adjust for confounding variables that lie on a common causal path between a hypothesized exposure (such as abundance of a microbial taxon) and the disease or condition under study. If variables are adjusted for in the analysis, theoretical justification for inclusion of these variables should be provided (Item 6.0). Consider including a directed acyclic graph showing the hypothesized causal relationships of interest.(16) Additionally discuss the potential for selection or survival bias (Item 6.1). For example, such bias may occur due to loss-to-follow-up (in longitudinal studies) or due to participants not being included in the study due to the condition itself (e.g. participants who have died of aggressive forms of colorectal cancer have not survived to be in a hypothetical study of colorectal cancer microbiomes).(17)

Bioinformatics and Statistical Methods

Adequate description of bioinformatic and statistical methods is essential to producing a rigorous and reproducible research report. Transformations of quantitative variables (such as normalization, rarefaction, and percentages) should be described (Item 7.0). All statistical methods used to analyze the data should be stated, (Item 7.1) including how results of interest were selected (e.g. using a p-value or other threshold) (Item 7.6). In the interest of reproducibility, all software, packages, databases, and libraries used for the analysis of the data should be described and cited including version numbers (Item 7.7).

Results

Outcome Data

The main outcomes of the study should be detailed including descriptive information, findings of interest, and the results of any additional analyses. Descriptive microbiome analysis (for instance, dimension reduction such as Principal Coordinates Analysis, measures of diversity, gross taxonomic composition) should be reported for each group and each time point (Item 9.0). This contextualizes the results of differential abundance analysis for readers. When reporting differential abundance test results, the magnitude and direction of differential abundance should be clearly stated (Item 9.1) for each identifiable standardized taxonomic unit (Item 9.2). Some results (e.g. non-significant results) can be included in supplements, but should not be excluded entirely. Although the problem has been known for decades,(18) journals across many fields are recognizing the issue of publication bias and therefore the issue of non-reporting of null results.(19) Including such results in publications will help to reduce the severity of this bias and improve future systematic reviews and meta-analyses.

Discussion

Most recommendations for the Discussion section remain unchanged from STROBE. One additional recommendation is made: discuss the potential for bias and how they would influence the study findings (Item 12.1). Many forms of bias such as measurement bias or selection bias(20) could affect the interpretation of the results of the study and it is important to acknowledge potential sources of bias when discussing the results.(21) If different forms of bias were not assessed or assumed to be negligible, this should be stated.

Other Information

Reproducible research practices serve as quality checks in the process of publication and further transparency and knowledge sharing.(18) Journals are increasingly implementing reproducible research standards that include the publishing of data and code and those guidelines should be followed when possible.(23,24) STORMS itemizes the accessibility of data and code (Items 18.0 through 18.4). If data or code are not made publicly available, an explanation should be given.

Discussion

The STORMS guidelines can improve the quality and communication of studies of the human microbiome, by introducing a shared grammar of study reporting for the field. They encourage reproducibility and open data sharing, and ease barriers to conducting systematic reviews and meta-analyses. The development of STORMS is an ongoing process and new versions of the checklist will be released to reflect evolving standards and technological processes. We invite interested readers to join the working group by contacting the corresponding author or by visiting the working group website for more information (storms.waldronlab.io). We also encourage journals to include the STORMS checklist in their instructions to authors and advise peer reviewers to consult the checklist when reviewing submissions.

There are some limitations to the STORMS checklist. The checklist was not created to assess study or methodological rigor. It is meant to make it easy for readers to assess how a study was conducted and analyzed. Conclusions about the quality of studies should not be made based on their adherence to STORMS guidelines, although it is our hope that the reporting guidelines will help readers review studies critically. It does not encourage, discourage, or assume the use of null hypothesis significance testing(22) or methods of compositional data analysis,(23) topics of some controversy in the field. In general the checklist avoids reference to or guidance on specific statistical methodological decisions.

The working group believes that the STORMS checklist is sufficiently flexible and “user-friendly” to support widespread adoption and contribution to microbiome study standards.

Its adoption will encourage thoughtful study design, study reproducibility, collaboration, and open knowledge sharing between research groups as they explore the human microbiome.

Bibliography

1. Moher D, Jones A, Lepage L, et al. Use of the CONSORT Statement and Quality of Reports of Randomized Trials: A Comparative Before-and-After Evaluation. *JAMA*. 2001;285(15):1992–1995.
2. Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. 2006;185(5):5.
3. The EQUATOR Network | Enhancing the QUALity and Transparency Of Health Research. (<http://www.equator-network.org/>). (Accessed September 23, 2019)
4. Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data | BMC Medicine | Full Text. (<https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-019-1301-1>). (Accessed January 29, 2020)
5. STROGAR – STrengthening the Reporting Of Genetic Association studies in Radiogenomics - ScienceDirect. (<https://www.sciencedirect.com/science/article/pii/S0167814013003630>). (Accessed January 29, 2020)
6. Sinha R, Abnet CC, White O, et al. The microbiome quality control project: baseline study design and future directions. *Genome Biol*. 2015;16(1):276.
7. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies - ScienceDirect. (<https://www.sciencedirect.com/science/article/pii/S0895435607004362>). (Accessed January 29, 2020)
8. STrengthening the REporting of Genetic Association Studies (STREGA)—an extension of the STROBE statement - Little - 2009 - Genetic Epidemiology - Wiley Online Library. (<https://onlinelibrary.wiley.com/doi/abs/10.1002/gepi.20410>). (Accessed January 29, 2020)
9. Sinha R, Ahsan H, Blaser M, et al. Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16–17, 2017. *Microbiome* [electronic article]. 2018;6. (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257978/>). (Accessed September 20, 2019)
10. Hornung BVH, Zwitter RD, Kuijper EJ. Issues and current standards of controls in microbiome research. *FEMS Microbiol. Ecol.* [electronic article]. 2019;95(5). (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469980/>). (Accessed March 16, 2020)
11. Pearce N. Classification of epidemiological study designs. *Int. J. Epidemiol.* 2012;41(2):393–397.
12. Jin Y, Wu S, Zeng Z, et al. Effects of environmental pollutants on gut microbiota. *Environ. Pollut.* 2017;222:1–9.
13. Chen L, Zhang Y-H, Huang T, et al. Gene expression profiling gut microbiota in different races of humans. *Sci. Rep.* 2016;6:23075.
14. Yatsunencko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. *Nature*. 2012;486(7402):222–227.
15. Yan L, Ma C, Wang D, et al. OSAT: a tool for sample-to-batch allocations in genomics experiments. *BMC Genomics*. 2012;13:689.
16. Textor J, van der Zander B, Gilthorpe MS, et al. Robust causal inference using directed

- acyclic graphs: the R package 'dagitty.' *Int. J. Epidemiol.* 2017;dyw341.
17. Schooling CM. Selection bias in population-representative studies? A commentary on Deaton and Cartwright. *Soc. Sci. Med.* 1982. 2018;210:70.
 18. Rosenthal R. The file drawer problem and tolerance for null results. (<http://pages.ucsd.edu/~cmckenzie/Rosenthal1979PsychBulletin.pdf>). (Accessed March 23, 2020)
 19. Null is beautiful: On the importance of publishing null results - Marcus Munafò, Jo Neill, 2016. (<https://journals.sagepub.com/doi/full/10.1177/0269881116638813>). (Accessed March 23, 2020)
 20. Hernán M, Robins, JM. Causal Inference: What If. Boca Raton, FL: Chapman & Hall/CRC; 2020 (Accessed May 29, 2020). (<https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/>). (Accessed May 29, 2020)
 21. Writing a discussion section: how to integrate substantive and statistical expertise | BMC Medical Research Methodology | Full Text. (<https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-018-0490-1>). (Accessed March 23, 2020)
 22. Szucs D, Ioannidis JPA. When Null Hypothesis Significance Testing Is Unsuitable for Research: A Reassessment. *Front. Hum. Neurosci.* [electronic article]. 2017;11. (<https://www.frontiersin.org/articles/10.3389/fnhum.2017.00390/full>). (Accessed June 17, 2020)
 23. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, et al. Microbiome Datasets Are Compositional: And This Is Not Optional. *Front. Microbiol.* [electronic article]. 2017;8. (<https://www.frontiersin.org/articles/10.3389/fmicb.2017.02224/full?report=reader>). (Accessed June 17, 2020)

| Number | Item | Recommendation | Source | Additional Guidance | Yes/No/NA | Comments | Relevant Text from article |
|---------------------|------------------------------|---|-----------------|--|-----------|----------|----------------------------|
| Abstract | | | | | | | |
| 1.0 | Study Design | Study design is stated in the abstract. | STORMS | Examples: case-control (participants with condition of interest are matched to controls), cross-sectional (data collected at one time point, no matching done between cases and controls), randomized controlled trial (condition is randomly assigned to participants), time series (participants are followed over time to observe changes), cohort (participants are followed over time to see who develops the condition of interest and who does not). For more information about common study designs see: https://doi.org/10.1592/phco.30.10.973 | | | |
| Introduction | | | | | | | |
| 2.0 | Background and Rationale | State underlying background, scientific evidence, or theory driving the current hypothesis. If the study is exploratory, state what drives the current exploration. | STORMS | | | | |
| Methods | | | | | | | |
| 3.0 | Participants | State what the population of interest is, and the method by which participants are sampled from that population. | STORMS | Examples of the population of interest could be: adults with no chronic health conditions, adults with type II diabetes, newborns, etc. This is the total population to whom the study is hoped to be generalizable to. The sampling method describes how potential participants were selected from that population. This includes the geographic region where participants were sampled from. | | | |
| 3.1 | Eligibility criteria | List any criteria for inclusion and exclusion of recruited participants. | Modified STROBE | Among potential recruited participants, how were some chosen and others not? | | | |
| 3.2 | Analytic sample size | Explain how the final analytic sample size was calculated, including the number of cases and controls if relevant, and reasons for dropout at each stage of the study. This should include the number of individuals in whom microbiome sequencing was attempted and the number in whom microbiome sequencing was successful. | STORMS | Consider use of a flow diagram (from STROBE). | | | |
| 3.3 | Loss to follow-up | For longitudinal studies, describe sample size at follow-up by group or condition and discuss any loss to follow-up. | STORMS | If there is loss to follow-up, discuss the likelihood that drop-out is associated with exposures, treatments, or outcomes of interest. | | | |
| 3.4 | Matching | For matched studies, give matching criteria. | Modified STROBE | "Matched" refers to matching between comparable study participants as cases and controls or exposed / unexposed. | | | |
| 4.0 | Laboratory | State the body site sampled from and how samples were collected. | STORMS | | | | |
| 4.1 | Batch effects | Discuss any likely sources of batch effects, if known. Detail any blocking or randomization used in study design to avoid confounding of batches with exposures or outcomes. | STORMS | Batch effects are unavoidable in all but the smallest genomic studies, and can be introduced by subtle differences in sample collection, storage, library preparation, and sequencing. | | | |
| 4.2 | Storage | Storage. State the laboratory/center where laboratory work was done. Describe how the laboratory stored samples, including time between collection and storage as well as any preservation buffers used. | STORMS | State where each procedure or lot of samples was done if not all in the same place. | | | |
| 4.3 | Laboratory methods | Describe laboratory methods including (where relevant): collection, shipping, extraction (including kit and version), human DNA removal (if applicable), amplification, primer selection, and contaminant analysis/negative controls. | STORMS | For amplicon sequencing (for example, 16S variable region), state the region selected. If enrichment is performed (e.g. for viromes), include here. Note any modifications of lab protocols and the reason for protocol modifications. | | | |
| 4.4 | Sequencing | Describe sequencing methods and platforms as well as any profiling software used (name and version). | STORMS | | | | |
| 4.5 | Controls | Describe positive and negative controls used in extraction, sequencing, preprocessing, and/or analysis. | STORMS | | | | |
| 5.0 | Data sources/ measurement | For each non-microbiome variable, including the health condition of interest, state how it was measured or collected. | STORMS | State any sources of potential bias in measurements, for example multiple interviewers or measurement instruments, and whether these potential biases were assessed or accounted for in study design. | | | |

| Number | Item | Recommendation | Source | Additional Guidance | Yes/No/NA | Comments | Relevant Text from article |
|--------------------------|---------------------------------------|---|-----------------|---|-----------|----------|----------------------------|
| 6.0 | Research design for causal | State which variables are controlled and state the rationale for controlling for them within your hypothesized causal framework. | STORMS | For example, hypothesized confounders may be controlled for by multivariate adjustment, but colliders or mediators should not be. Consider using a Directed Acyclic Graph (DAG) to summarize hypothesized causal pathways. | | | |
| 6.1 | Selection bias | Discuss potential for selection or survival bias. | STORMS | Selection bias can occur when some members of the target study population are more likely to be selected for the study than others. Some examples include survival bias (where part of the target study population is more likely to die before they can be studied), convenience sampling (where members of the target study population are not selected at random), and loss to follow-up (when probability of dropping out is related to one of the things being studied). | | | |
| 7.0 | Bioinformatic and Statistical Methods | Describe any transformations to quantitative variables used in analyses (e.g. use of percentages instead of counts, normalization, rarefaction, categorization). | STORMS | | | | |
| 7.1 | Statistical methods | Describe all statistical methods. | Modified STROBE | | | | |
| 7.2 | Subgroup analysis | Describe any methods used to examine subgroups and interactions. | STROBE | | | | |
| 7.3 | Missing data | Explain how missing data were addressed. | STROBE | | | | |
| 7.4 | Methods for sampling | If applicable, describe methods taking into account of sampling strategy/survey design. | Modified STROBE | This could include using methods that adjust for stratification, clustering, or sample weighting. | | | |
| 7.5 | Sensitivity analyses | Describe any sensitivity analyses. | STROBE | | | | |
| 7.6 | Findings | State criteria used to select findings for reporting. | STORMS | For example, false discovery rate with total number of tests, effect size threshold, significance threshold, microbes of interest. | | | |
| 7.7 | Software | Cite all software (including read mapping software) and databases (including any used for annotating amplicons, if applicable) used. Include version numbers. | Modified STREGA | For R, installed package versions should be stated and cited in addition to the version of R used. | | | |
| Results | | | | | | | |
| 8.0 | Descriptive Data | Give characteristics of study participants (e.g. dietary, demographic, clinical, social) and information on exposures and potential confounders. | STROBE | Typically reported in Table 1. Indicate number of participants with missing data for each variable of interest This includes environmental and lifestyle factors that may be important to the relationship between the microbiome and the condition of interest. Participant diet and medication use should be summarized, if known. At the very minimum, age and sex of all participants should be reported. | | | |
| 9.0 | Outcome Data | Report descriptive findings for microbiome analyses by group and (if applicable) by time. | STORMS | | | | |
| 9.1 | Differential abundance | Report results of differential abundance analysis by group and (if applicable) by time, clearly indicating the direction of change. | STORMS | | | | |
| 9.2 | Taxonomy | Identify taxonomy using standardized taxon classifications that are sufficient to uniquely identify taxa. | STORMS | If not using full taxonomic hierarchy, make sure it is clear whether names stated are species, genera, family, etc. Italicize genus/species pairs. | | | |
| 10.0 | Other analyses | Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses. | STROBE | | | | |
| Discussion | | | | | | | |
| 11.0 | Key results | Summarise key results with reference to study objectives | STROBE | | | | |
| 12.0 | Limitations | Discuss limitations of the study, taking into account sources of potential bias or imprecision. | STROBE | | | | |
| 12.1 | | Discuss any potential for bias to influence study findings. | STORMS | | | | |
| 13.0 | Interpretation | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence. | STROBE | Define or clarify any subjective terms such as "dominant," "dysbiosis," and similar words used in interpretation of results. | | | |
| 14.0 | Generalizability | Discuss the generalisability (external validity) of the study results | STROBE | | | | |
| Other information | | | | | | | |

| Number | Item | Recommendation | Source | Additional Guidance | Yes/No/NA | Comments | Relevant Text from article |
|--------|-------------------------|---|--------|--|-----------|----------|----------------------------|
| 15.0 | Funding | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | STROBE | | | | |
| 16.0 | Supplements | Indicate where supplements may be accessed and what materials they contain | STORMS | | | | |
| 17.0 | Supplementary data | Provide a supplementary spreadsheet of results with for all taxa and all outcome variables analyzed. Indicate the taxonomic level of all taxa. | STORMS | Depending on the analysis performed, examples of the supplemental results included could be mean relative abundance, differential abundance, raw p-value, MHT-adjusted p-values, and standard error. All discussed taxa should include the taxonomic level (e.g. class, order, genus) | | | |
| 18.0 | Reproducible research | (a) State where raw data may be accessed including demultiplexing information. | STORMS | | | | |
| 18.1 | Processed data access | (b) State where processed data may be accessed. | STORMS | | | | |
| 18.2 | Participant data access | (c) State where participant data may be accessed. | STORMS | | | | |
| 18.3 | Source code access | (d) State where code may be accessed. | STORMS | | | | |
| 18.4 | Full results | (e) Provide full results of all analyses, in computer-readable format, in supplementary materials. | STORMS | For example, any fold-changes, p-values, or FDR values calculated. | | | |